Karyopharm to Report First Quarter 2026 Financial Results on May 14, 2026

Karyopharm (Nasdaq: KPTI) will report first quarter 2026 financial results on Thursday, May 14, 2026.

Rhea-AI Summary

Karyopharm (Nasdaq: KPTI) will report first quarter 2026 financial results on Thursday, May 14, 2026. Management will host a conference call and live audio webcast at 8:00 a.m. ET to discuss results and company updates. Slides and an archived webcast will be available on the investor website approximately two hours after the event.

Argus May 7 session

-1.88% close to close Open Argus

Details

News Market Reaction – KPTI

On May 7, the day this news came out, KPTI closed 1.88% below the previous close.

Data tracked by StockTitan Argus for the May 7 session.

Market Context

This announcement sets the timeline for first-quarter 2026 financial results on May 14, 2026 with an...

Analysis

This announcement sets the timeline for first-quarter 2026 financial results on May 14, 2026 with an 8:00 a.m. ET call, following Karyopharm’s established communication pattern. In recent months, investors have also seen substantial clinical and financing updates, plus an S-3 resale registration for 8,843,036 shares. Attention naturally turns to the forthcoming earnings metrics and any revisions to prior 2026 revenue guidance.

Key Figures

Earnings date: May 14, 2026 Conference time: 8:00 a.m. ET Dial-in lead time: 10 minutes

Earnings date

May 14, 2026

Scheduled first quarter 2026 financial results release

Conference time

8:00 a.m. ET

Management call to discuss Q1 2026 results

Dial-in lead time

10 minutes

Requested arrival before call start

Previous Earnings date Reports

1 past event · Latest: Feb 05

Same Type 1 event

1. Feb 05

   Earnings date set

   24h Move

   -3.3%

   Scheduled Q4 and full-year 2025 results with 8:00 a.m. ET call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

-- Conference Call Scheduled for Thursday, May 14, 2026, at 8:00 a.m. ET --

NEWTON, Mass., May 7, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report first quarter 2026 financial results on Thursday, May 14, 2026. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Thursday, May 14, 2026, to discuss the financial results and other company updates.

To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. An archived webcast will be available on the Company's website approximately two hours after the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO^® (selinexor), is approved in the U.S. and marketed by the Company in two oncology indications. It has also received regulatory approvals in various indications in more than 50 ex-U.S. territories and countries, including the European Union, the United Kingdom (as NEXPOVIO^®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, and myelofibrosis. For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-report-first-quarter-2026-financial-results-on-may-14-2026-302764337.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Karyopharm (KPTI) release its Q1 2026 financial results?

Karyopharm will release Q1 2026 financial results on May 14, 2026 at 8:00 a.m. ET. According to Karyopharm, management will discuss financial results and company updates during a conference call and live webcast the same morning.

How can investors join the Karyopharm (KPTI) earnings call on May 14, 2026?

Investors can join by dialing (800) 836-8184 (U.S.) or (646) 357-8785 (international) at least 10 minutes early. According to Karyopharm, callers should ask to be joined into the Karyopharm Therapeutics call.

Where will the Karyopharm (KPTI) webcast and slides be posted for the May 14, 2026 call?

The live audio webcast and accompanying slides will be posted under Events & Presentations on the company's investor website. According to Karyopharm, an archived webcast will be available about two hours after the event.

Will Karyopharm (KPTI) provide a replay of the May 14, 2026 earnings webcast?

Yes. An archived webcast will be available approximately two hours after the live event on the investor website. According to Karyopharm, the replay and slides will remain accessible in the Events & Presentations section for later review.

What time should I join the Karyopharm (KPTI) conference call on May 14, 2026?

Join at least 10 minutes before the 8:00 a.m. ET start time to ensure entry to the call. According to Karyopharm, callers should dial the provided numbers early and request to be joined into the Karyopharm Therapeutics call.